• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chemotherapy Research and Practice >Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?
【24h】

Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?

机译：预测性分子肿瘤测试：板凳和床边之间的障碍是什么？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There have been many exciting new breakthroughs in understanding tumour biology. This has opened up the possibility of personalized treatment for people with certain tumours. The epidermal growth factor receptor (EGFR) and K-ras are two such targets that can help classify tumours on a molecular basis and guide treatment decisions. However, there are still questions about how best to implement new molecular tests like these to characterize tumours in clinical practice. Potential obstacles include availability of good quality tissue specimens, access to the right test, and consensus about interpretation, funding, and availability. In this paper, we review these issues, by discussing these two examples in detail and suggest some actions for addressing potential barriers.
机译：在理解肿瘤生物学方面有许多令人兴奋的新突破。这为患有某些肿瘤的人提供了个性化治疗的可能性。表皮生长因子受体（EGFR）和K-ras是两个这样的靶标，可以帮助在分子基础上对肿瘤进行分类并指导治疗决策。但是，仍然存在关于如何最好地实施此类新分子测试以表征临床实践中的肿瘤的问题。潜在的障碍包括优质组织标本的可用性，获得正确测试的机会以及关于解释，资金和可用性的共识。在本文中，我们通过详细讨论这两个示例来回顾这些问题，并提出一些解决潜在障碍的措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号